Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
Astria Therapeutics (Nasdaq: ATXS) has announced its upcoming presentation of interim quality of life results from the ALPHA-STAR trial of navenibart (STAR-0215) at the Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting in Banff, Alberta. The presentation will take place on November 7, 2024.
Dr. Adil Adatia from the University of Alberta will present a poster focusing on quality of life improvements in hereditary angioedema (HAE) patients treated with STAR-0215. The poster will be displayed in the Van Horne Foyer from 10:00am MDT on November 7 until November 9.
Astria Therapeutics (Nasdaq: ATXS) ha annunciato la prossima presentazione dei risultati intermedi sulla qualità della vita del trial ALPHA-STAR relativo al navenibart (STAR-0215) durante il Meeting Scientifico Annuale della Canadian Society of Allergy and Clinical Immunology a Banff, Alberta. La presentazione si svolgerà il 7 novembre 2024.
Il Dr. Adil Adatia dell'Università dell'Alberta presenterà un poster incentrato sui miglioramenti della qualità della vita nei pazienti con angioedema ereditario (HAE) sottoposti a trattamento con STAR-0215. Il poster sarà esposto nel Van Horne Foyer dalle 10:00 MDT del 7 novembre fino al 9 novembre.
Astria Therapeutics (Nasdaq: ATXS) ha anunciado su próxima presentación de resultados intermedios sobre la calidad de vida del ensayo ALPHA-STAR del navenibart (STAR-0215) en el Congreso Anual de la Canadian Society of Allergy and Clinical Immunology en Banff, Alberta. La presentación tendrá lugar el 7 de noviembre de 2024.
El Dr. Adil Adatia de la Universidad de Alberta presentará un póster centrado en las mejoras de la calidad de vida en pacientes con angioedema hereditario (HAE) tratados con STAR-0215. El póster se exhibirá en el Van Horne Foyer desde las 10:00 am MDT del 7 de noviembre hasta el 9 de noviembre.
아스트리아 테라퓨틱스 (Nasdaq: ATXS)는 알버타주 반프에서 열리는 캐나다 알레르기 및 임상 면역학회 연례 과학 회의에서 navenibart (STAR-0215)에 대한 ALPHA-STAR 시험의 중간 삶의 질 결과를 발표할 예정이라고 발표했습니다. 발표는 2024년 11월 7일에 진행됩니다.
앨버타대학교의 아딜 아다티아 박사는 STAR-0215로 치료받은 유전성 혈관부종(HAE) 환자의 삶의 질 개선에 초점을 맞춘 포스터를 발표합니다. 포스터는 11월 7일 오전 10시 MDT부터 11월 9일까지 Van Horne Foyer에 전시됩니다.
Astria Therapeutics (Nasdaq: ATXS) a annoncé sa prochaine présentation des résultats intermédiaires sur la qualité de vie de l'
Dr. Adil Adatia de l'Université de l'Alberta présentera une affiche axée sur les améliorations de la qualité de vie chez les patients atteints d'angioédème héréditaire (HAE) traités avec STAR-0215. L'affiche sera exposée au Van Horne Foyer à partir de 10h00 MDT le 7 novembre jusqu'au 9 novembre.
Astria Therapeutics (Nasdaq: ATXS) hat die bevorstehende Präsentation der vorläufigen Ergebnisse zur Lebensqualität aus der ALPHA-STAR-Studie mit navenibart (STAR-0215) auf dem Jahrestreffen der Canadian Society of Allergy and Clinical Immunology in Banff, Alberta, angekündigt. Die Präsentation findet am 7. November 2024 statt.
Dr. Adil Adatia von der Universität Alberta wird ein Plakat präsentieren, das sich mit den Verbesserungen der Lebensqualität bei Patienten mit hereditärem Angioödem (HAE) befasst, die mit STAR-0215 behandelt wurden. Das Plakat wird vom 7. November um 10:00 MDT bis zum 9. November im Van Horne Foyer ausgestellt.
- None.
- None.
Adil Adatia, M.D., Assistant Professor in the Department of Medicine at the University of
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030578125/en/
Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
When will Astria Therapeutics (ATXS) present the ALPHA-STAR trial results?
What is the focus of Astria Therapeutics' (ATXS) ALPHA-STAR trial presentation?
Where will the ATXS ALPHA-STAR trial poster be displayed?
Who will present the Astria Therapeutics (ATXS) ALPHA-STAR trial results?
